Home | All trials

[RDF data]
Trial NCT00805857

Resource URI: http://static.linkedct.org/resource/trials/NCT00805857
PropertyValue
linkedct:brief_title Surveillance Cohort Long-Term Toxicity Antiretrovirals in HIV-Infected Patients Enrolled in TPV Cohort
linkedct:condition <http://static.linkedct.org/resource/condition/5486>
linkedct:criteria Inclusion Criteria: - All patients > 18 years old HIV infected treated with tipranavir Exclusion Criteria:
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age N/A
linkedct:eligibility_minimum_age 18 Years
linkedct:enrollment 150 (xsd:int)
linkedct:firstreceived_date June 10, 2008
linkedct:id NCT00805857
rdfs:label Trial NCT00805857
linkedct:lastchanged_date December 9, 2008
linkedct:lead_sponsor_agency Boehringer Ingelheim Pharmaceuticals
linkedct:nct_id NCT00805857
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:official_title SCOLTA: SURVEILLANCE COHORT LONG-TERM TOXICITY ANTIRETROVIRALS
linkedct:org_study_id 1182.144
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/6229>
linkedct:overall_status Withdrawn
linkedct:oversight <http://static.linkedct.org/resource/oversight/1473>
foaf:page <http://clinicaltrials.gov/show/NCT00805857>
linkedct:phase N/A
linkedct:primary_completion_date December 2009
linkedct:primary_outcomes <http://static.linkedct.org/resource/primary_outcomes/44886>
linkedct:secondary_outcomes <http://static.linkedct.org/resource/secondary_outcomes/109489>
linkedct:source Boehringer Ingelheim Pharmaceuticals
linkedct:start_date June 2008
linkedct:study_design N/A
linkedct:study_type Observational
linkedct:summary The SCOLTA project is a system for online surveying of adverse events to recently commercialized antiretroviral drugs and a sentinel for unexpected and late adverse events reactions arising during any antiretroviral treatment.Aim of the proposed study is: 1. to evaluate the prevalence and incidence of serious adverse events and serious unexpected adverse events in HIV-infected patients enrolled in the SCOLTA project Tipranavir cohort and to identify possible risk factors 2. the evaluation of tipranavir containing regimens durability, considering treatment interruption for each reason.
rdf:type linkedct:trials
linkedct:verification_date December 2008